logo
logo

Valted Seq Raises $10.5 Million In Seed Funding Round

Nov 02, 2021•over 3 years ago

Amount Raised

$10.5 Million

Round Type

seed

Gaithersburg

Description

Valted Seq, a biotechnology company focused on the genetic elucidation of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, today announced the completion of a seed fundraising round totaling $10.5 million. Dongkoo Bio&Pharma Co. Ltd. led the financing round which also included new investor OV Principal Investments, LLC and several independent investors

Company Information

Company

Valted Seq

Location

Gaithersburg, Maryland, United States

About

Valted Seq is focused on the discovery of neurodegenerative disease pathways to accelerate development of new therapeutics and diagnostics, including companion diagnostics which play a critical role in enabling advanced therapeutics. Using its HiF-Seq platform, the company has created the world’s largest repository of transcriptomic data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimer’s and Parkinson’s. Valted Seq was co-founded in 2019 by Ted Dawson, Valina Dawson and D&D Pharmatech. For more information, please visit www.valtedseq.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech